Article Text

other Versions

PDF

Persistent clinical efficacy and safety of anti-TNFα therapy with infliximab in patients with ankylosing spondylitis over 5 years - evidence for different types of response
  1. J Braun (j.braun{at}rheumazentrum-ruhrgebiet.de)
  1. Rheumazentrum Ruhrgebiet, Germany
    1. X Baraliakos (xenob{at}onlinehome.de)
    1. Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Germany
      1. J Listing (listing{at}drfz.de)
      1. German Rheumatism Research Centre, Germany
        1. C Fritz (fritz{at}drfz.de)
        1. German Rheumatism Research Centre, Germany
          1. R Alten (rieke.alten{at}schlosspark-klinik.de)
          1. Schlosspark-Clinic, Germany
            1. G Burmester (gerd.burmester{at}charite.de)
            1. Charite University Hospital, Germany
              1. A Krause (a.krause{at}immanuel.de)
              1. Immanuel-Krankenhaus Rheumaklinik Wannsee, Germany
                1. S Schewe
                1. LMU München, Rheumatology, Germany
                  1. M Schneider (schneider{at}rheumanet.org)
                  1. Heinrich-Heine-University, Düsseldorf, Germany
                    1. H Soerensen
                    1. Rheumatology Praxis, Berlin, Germany
                      1. H Zeidler
                      1. Medical University Hannover, Germany
                        1. J Sieper (joachim.sieper{at}charite.de)
                        1. University Clinic Benjamin Franklin, Germany

                          Abstract

                          Background: There is insufficient evidence for the long-term efficacy and safety of anti-TNF therapy in patients with ankylosing spondylitis (AS). This is the first report on treatment with infliximab over 5 years.

                          Methods: As part of a multicener randomized trial, 69 patients with active AS at baseline (BL) have been continuously treated with infliximab (5mg/kg i.v./6w)-except for a short discontinuation after 3 years (FU1). The primary outcome of this extension was remission according to the ASAS criteria at the end of year 5 of the study (FU2).

                          Results: Of the 43 patients who completed year 3, 42 agreed to continue, 38 of which (90.5%) finished year 5 (55% of 69 initially). Partial clinical remission was achieved in 13/38 patients (34.2%) at FU1 and FU2. At FU2, the mean BASDAI was 2.5±1.9 (BL:6.4, FU1:2.5). BASDAI values <4 were seen in 79% of patients at both, FU1 and FU2. ASAS 20% and 40% responses were seen in 32 (84%) and 24 (63%) patients at FU2, respectively. Most patients classified as non-responders at FU2 were part time responders, since all but one patient achieved an ASAS20% response at least once within the last 2 years. Three types of responders were identified. No major side effects occurred during year 4 and 5 of infliximab therapy.

                          Conclusions: Infliximab is safe and efficacious in AS patients over 5 years. The majority of the patients remained on treatment and had rather persistent levels of low disease activity. Different response types could be identified.

                          • TNFalpha
                          • ankylosing spondylitis
                          • infliximab
                          • response types

                          Statistics from Altmetric.com

                          Request permissions

                          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.